NO990700L - Propionsyrederivater og anvendelsen herav - Google Patents

Propionsyrederivater og anvendelsen herav

Info

Publication number
NO990700L
NO990700L NO990700A NO990700A NO990700L NO 990700 L NO990700 L NO 990700L NO 990700 A NO990700 A NO 990700A NO 990700 A NO990700 A NO 990700A NO 990700 L NO990700 L NO 990700L
Authority
NO
Norway
Prior art keywords
propionic acid
acid derivatives
derivatives
propionic
acid
Prior art date
Application number
NO990700A
Other languages
English (en)
Other versions
NO990700D0 (no
NO312160B1 (no
Inventor
Hisashi Shinkai
Tsutomu Shibata
Satoshi Ohrui
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP21754896A external-priority patent/JP3215048B2/ja
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO990700D0 publication Critical patent/NO990700D0/no
Publication of NO990700L publication Critical patent/NO990700L/no
Publication of NO312160B1 publication Critical patent/NO312160B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20Quaternary compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19990700A 1996-08-19 1999-02-15 Propionsyrederivater og farmasöytiske sammensetninger inneholdende disse NO312160B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21754896A JP3215048B2 (ja) 1996-04-03 1996-08-19 プロピオン酸誘導体及びその用途
PCT/JP1997/002873 WO1998007699A1 (fr) 1996-08-19 1997-08-19 Derives d'acide propionique et applications de ces derives

Publications (3)

Publication Number Publication Date
NO990700D0 NO990700D0 (no) 1999-02-15
NO990700L true NO990700L (no) 1999-04-19
NO312160B1 NO312160B1 (no) 2002-04-02

Family

ID=16705991

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990700A NO312160B1 (no) 1996-08-19 1999-02-15 Propionsyrederivater og farmasöytiske sammensetninger inneholdende disse

Country Status (17)

Country Link
US (1) US6204277B1 (no)
EP (1) EP0930299A1 (no)
KR (1) KR20000068151A (no)
CN (1) CN1233241A (no)
AU (1) AU740444B2 (no)
BG (1) BG103268A (no)
BR (1) BR9711627A (no)
CA (1) CA2263721A1 (no)
CZ (1) CZ53699A3 (no)
EE (1) EE03765B1 (no)
IL (1) IL128600A0 (no)
NO (1) NO312160B1 (no)
NZ (1) NZ334738A (no)
PL (1) PL331861A1 (no)
RU (1) RU2174121C2 (no)
SK (1) SK21099A3 (no)
WO (1) WO1998007699A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515133A (ja) * 1996-07-01 2000-11-14 イーライ・リリー・アンド・カンパニー 血糖降下性および脂質低下性の化合物
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
WO1999046232A1 (fr) 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2002533318A (ja) * 1998-12-22 2002-10-08 ニューロサーチ、アクティーゼルスカブ イオンチャネル調節剤
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ(チア)ゾール誘導体およびそのpparモジュレーターとしての使用
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
ATE407919T1 (de) * 2000-05-29 2008-09-15 Kyorin Seiyaku Kk Substituierte phenylpropionsäure-derivate
US6525095B1 (en) * 2000-07-10 2003-02-25 New Mexico State University Technology Transfer Corporation Propionate feed supplement
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
SK1872003A3 (en) * 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
AU2001284660A1 (en) * 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
KR100474137B1 (ko) * 2001-11-16 2005-03-08 (주)바이오뉴트리젠 신규의 아릴프로피온산 유도체 및 이를 포함하는 당뇨병 예방 또는 치료용 조성물
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
CA2473207A1 (en) * 2002-01-17 2003-07-24 Toa Eiyo Ltd. Halogenobenzylaminopropionic acid derivatives
US20050084840A1 (en) * 2002-01-23 2005-04-21 Hideki Endoh Method for screening drug for improving insulin resistance
DE60324898D1 (de) 2002-02-25 2009-01-08 Lilly Co Eli Modulatoren von peroxisome proliferator-aktivierten rezeptoren
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6716842B2 (en) * 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
RS20050426A (en) * 2002-11-15 2008-04-04 Cadila Healthcare Limited, Substituted aralkyl derivatives
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US7037384B2 (en) * 2003-06-23 2006-05-02 Bulk Chemicals, Inc. Lubricating chemical coating for metalworking
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
MX2007001634A (es) * 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
KR101497577B1 (ko) * 2012-07-31 2015-03-02 서울대학교산학협력단 2-에톡시프로피온산 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701420A (ko) 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
US5498621A (en) 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
TW268952B (no) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
JP3466273B2 (ja) * 1993-06-11 2003-11-10 武田薬品工業株式会社 テトラゾール誘導体、その製造法およびそれを含んでなる医薬
CA2157032C (en) * 1993-12-27 1999-09-28 Hisashi Shinkai Isoxazolidinedione derivative and use thereof
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−アミノ−3−フェニルプロピオン酸誘導体
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP2000515133A (ja) 1996-07-01 2000-11-14 イーライ・リリー・アンド・カンパニー 血糖降下性および脂質低下性の化合物

Also Published As

Publication number Publication date
EP0930299A1 (en) 1999-07-21
NZ334738A (en) 2001-01-26
KR20000068151A (ko) 2000-11-25
CA2263721A1 (en) 1998-02-26
CZ53699A3 (cs) 1999-07-14
US6204277B1 (en) 2001-03-20
WO1998007699A1 (fr) 1998-02-26
EP0930299A4 (no) 1999-07-21
PL331861A1 (en) 1999-08-16
IL128600A0 (en) 2000-01-31
BG103268A (en) 2000-12-29
NO990700D0 (no) 1999-02-15
SK21099A3 (en) 2000-05-16
RU2174121C2 (ru) 2001-09-27
NO312160B1 (no) 2002-04-02
CN1233241A (zh) 1999-10-27
BR9711627A (pt) 1999-08-24
AU3866597A (en) 1998-03-06
EE9900069A (et) 1999-10-15
EE03765B1 (et) 2002-06-17
AU740444B2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
NO990700L (no) Propionsyrederivater og anvendelsen herav
NO20000943L (no) 5-alkyl-2-arylaminofenyleddiksyrer og derivater
IS4481A (is) Díhýdrópyramídín og notkun þeirra
DE69703385D1 (de) Alkoxyessigsäure-derivate
NO990821D0 (no) Arylsulfonylamino-hydroksaminsyre-derivater
DE59703420D1 (de) Beta-Dithiophosphorylierte Propionsäure in Schmierstoffen
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
DK0934301T3 (da) Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer
NO984354D0 (no) Avisingsmiddel og anvendelse av dette
NO922291D0 (no) 7-azaisoindolinyl-kinolon- og naftyridonkarboksylsyrederivater
EP1024130A4 (en) BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
DK0906301T3 (da) Benzofurylderivater og anvendelsen deraf
NO975439D0 (no) Ketonderivater og medisinsk anvendelse derav
FI940216A0 (fi) Kinoloni- ja naftyridonikarboksyylihappojohdannaiset
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
ATE230734T1 (de) 3-alkoxyisoxazol-4-yl-substituierte 2- aminocarbonsäurederivate
NO971505D0 (no) Trofinin og trofininhjelperproteiner
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO20000184D0 (no) Nye purinderivater og medisinsk anvendelse derav
IS1813B (is) Notkun á ferróseni og/eða ferrósenafleiðum
IS4924A (is) Píperidín ediksýruafleiður og notkun þeirra við meðhöndlun á segamyndunar truflunum
NO983556D0 (no) Formulering og anvendelse
NO981002L (no) Karboksylsyrederivater, deres fremstilling og anvendelse
NO985928L (no) 19Fluor merket antracyklinon og antracyklinderivater